BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 8252157)

  • 21. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group.
    Tamura K
    Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S123-7; discussion S133-40. PubMed ID: 16249072
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Empiric monotherapy in neutropenia: a realistic goal?
    Del Favero A; Bucaneve G; Menichetti F
    Scand J Infect Dis Suppl; 1995; 96():34-7. PubMed ID: 7652501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination of amikacin and ceftazidime as empiric treatment of febrile leukopenic patients affected by solid tumors.
    Gasparini G; Benedetti M; Fassio T; Canobbio L; Figoli F; Galligioni E; Talamini R; Toffoli G; Tumolo S
    Int J Clin Pharmacol Ther Toxicol; 1987 Feb; 25(2):113-20. PubMed ID: 3549581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Value of the combination of piperacillin and pefloxacin possibly followed by vancomycin in the treatment of febrile neutropenia in nephrotoxic chemotherapy].
    Kattan J; Droz JP; Culine S; Ribrag V; Boutan-Laroze A; Andremont A
    Bull Cancer; 1992; 79(7):705-12. PubMed ID: 1467596
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An open evaluation of triple antibiotic therapy including vancomycin for febrile bone marrow transplant recipients with severe neutropenia.
    Bosi A; Laszlo D; Bacci S; Fanci R; Guidi S; Saccardi R; Vannucchi AM; Rossi-Ferrini P
    J Chemother; 1999 Aug; 11(4):287-92. PubMed ID: 10465131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer.
    Jaksic B; Martinelli G; Perez-Oteyza J; Hartman CS; Leonard LB; Tack KJ
    Clin Infect Dis; 2006 Mar; 42(5):597-607. PubMed ID: 16447103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial.
    Harter C; Schulze B; Goldschmidt H; Benner A; Geiss HK; Hoppe-Tichy T; Ho AD; Egerer G
    Bone Marrow Transplant; 2006 Feb; 37(4):373-9. PubMed ID: 16400334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients.
    Vázquez L; Encinas MP; Morín LS; Vilches P; Gutiérrez N; García-Sanz R; Caballero D; Hurlé AD
    Haematologica; 1999 Mar; 84(3):231-6. PubMed ID: 10189388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies.
    Cherif H; Björkholm M; Engervall P; Johansson P; Ljungman P; Hast R; Kalin M
    Scand J Infect Dis; 2004; 36(8):593-600. PubMed ID: 15370671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ceftazidime plus amikacin plus teicoplanin or vancomycin in the empirical antibiotic therapy in febrile neutropenic cancer patients.
    Nucci M; Biasoli I; Braggio S; Portugal R; Schaffel R; Maiolino A; Loureiro MM; Spector N; Pulcheri W
    Oncol Rep; 1998; 5(5):1205-9. PubMed ID: 9683836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and tolerability of imipenem-cilastatin versus ceftazidime plus tobramycin as empiric therapy of presumed bacterial infection in neutropenic cancer patients.
    Miller JA; Butler T; Beveridge RA; Kales AN; Binder RA; Smith LJ; Ueno WM; Milkovich G; Goldwater S; Marion A
    Clin Ther; 1993; 15(3):486-99. PubMed ID: 8364941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Isepamicin once daily plus ceftriaxone versus amikacin plus ceftriaxone in febrile neutropenic patients.
    Herbrecht R; Blaise D; Espinouse D; Leblond V; Sadoun A; Sauvage C; Cordonnier C; Minozzi C
    J Chemother; 1995 Jun; 7 Suppl 2():103-10. PubMed ID: 8622099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Febrile neutropenia in cancer patients in a tertiary care medical center in Lebanon: microbial spectrum and outcome.
    Hamzeh F; Kanj SS; Uwaydah M
    J Med Liban; 2000; 48(3):136-42. PubMed ID: 11268566
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monotherapy with meropenem versus combination therapy with piperacillin plus amikacin as empiric therapy for neutropenic fever in children with lymphoma and solid tumors.
    Düzova A; Kutluk T; Kanra G; Büyükpamukçu M; Akyüz C; Seçmeer G; Ceyhan M
    Turk J Pediatr; 2001; 43(2):105-9. PubMed ID: 11432485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cefepime monotherapy is as effective as ceftriaxone plus amikacin in pediatric patients with cancer and high-risk febrile neutropenia in a randomized comparison.
    Pereira CA; Petrilli AS; Carlesse FA; Luisi FA; da Silva KV; de Martino Lee ML
    J Microbiol Immunol Infect; 2009 Apr; 42(2):141-7. PubMed ID: 19597646
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Therapy of febrile neutropenia episodes in systemic hematologic illnesses with new once daily ceftriaxone administration].
    Karthaus M; Südhoff T; Fenchel K; Egerer G; Kämpfe D; Ritter J; Franke A; Heil G; Peters G; Jürgens H
    Wien Med Wochenschr; 1998; 148(21):481-7. PubMed ID: 10048176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Empirical antimicrobial therapy in pediatric patients with neutropenia and fever. Risk factors for treatment failure.
    Miranda-Novales MG; Belmont-Martinez L; Villasis-Keever MA; Penagos-Paniagua M; Bernaldez-Rios R; Solorzano-Santos F
    Arch Med Res; 1998; 29(4):331-5. PubMed ID: 9887552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Addition of teicoplanin or vancomycin for the treatment of documented bacteremia due to gram-positive cocci in neutropenic patients with hematological malignancies: microbiological, clinical and economic evaluation.
    D'Antonio D; Staniscia T; Piccolomini R; Fioritoni G; Rotolo S; Parruti G; Di Bonaventura G; Manna A; Savini V; Fiorilli MP; Di Giovanni P; Francione A; Schioppa F; Romano F
    Chemotherapy; 2004 Jun; 50(2):81-7. PubMed ID: 15211082
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empirical therapy for neutropenic fever in children with malignancy.
    Hung KC; Chiu HH; Tseng YC; Wang JH; Lin HC; Tsai FJ; Peng CT
    J Microbiol Immunol Infect; 2003 Dec; 36(4):254-9. PubMed ID: 14723254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients.
    Rolston KV; Berkey P; Bodey GP; Anaissie EJ; Khardori NM; Joshi JH; Keating MJ; Holmes FA; Cabanillas FF; Elting L
    Arch Intern Med; 1992 Feb; 152(2):283-91. PubMed ID: 1739355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.